On the basis of evidence indicating that CD133 is a stem cell marker [12], we hypothesized that cCSCs, which are CD133-expressing CTCs, have a role in chemotherapy resistance and breast cancer prognosis. This evidence concerns the gene PROM1 and breast carcinoma.